Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Amortizatization of Intangibles (2016 - 2023)

Historic Amortizatization of Intangibles for Coherus Oncology (CHRS) over the last 9 years, with Q4 2023 value amounting to -$428000.0.

  • Coherus Oncology's Amortizatization of Intangibles fell 15350.0% to -$428000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 6257.19%. This contributed to the annual value of $4.2 million for FY2024, which is 7278.77% up from last year.
  • According to the latest figures from Q4 2023, Coherus Oncology's Amortizatization of Intangibles is -$428000.0, which was down 15350.0% from $601000.0 recorded in Q3 2023.
  • In the past 5 years, Coherus Oncology's Amortizatization of Intangibles registered a high of $3.7 million during Q1 2022, and its lowest value of -$428000.0 during Q4 2023.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $925000.0 (2020), whereas its average is $945750.0.
  • As far as peak fluctuations go, Coherus Oncology's Amortizatization of Intangibles skyrocketed by 26923.08% in 2022, and later plummeted by 15350.0% in 2023.
  • Quarter analysis of 5 years shows Coherus Oncology's Amortizatization of Intangibles stood at $613000.0 in 2019, then skyrocketed by 61.34% to $989000.0 in 2020, then grew by 11.93% to $1.1 million in 2021, then dropped by 27.73% to $800000.0 in 2022, then plummeted by 153.5% to -$428000.0 in 2023.
  • Its last three reported values are -$428000.0 in Q4 2023, $601000.0 for Q3 2023, and $895000.0 during Q2 2023.